# IMpassion131 (NCT03125902)

> A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03125902
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Triple-Negative Breast Cancer
- Interventions: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody; Atezolizumab Placebo; Paclitaxel
- Enrollment: 653
- Primary outcome: Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status
- Primary outcome: Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population

## Commentary we found

- YouTube: 10
- Podcasts: 10
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=impassion131-nct03125902

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03125902", "email": "<work email>"}; the inbox owner confirms by the emailed link.